Skip to content
Recovery & Performance PeptidesRecovery research and practical context
Recovery article

TB-500

TB-500 is a synthetic peptide derived from Thymosin Beta-4, a naturally occurring peptide in the body. It is recognized for its role in promoting healing, tissue repair, and anti-inflammatory effects. TB-500 enhances the migration and proliferation of cells, p

By Recovery & Performance Peptides Editorial Team

TB-500 is a synthetic peptide derived from Thymosin Beta-4, a naturally occurring peptide in the body. It is recognized for its role in promoting healing, tissue repair, and anti-inflammatory effects. TB-500 enhances the migration and proliferation of cells, particularly endothelial cells, and supports the formation of new blood vessels (angiogenesis). Due to these properties, TB-500 is studied for its potential therapeutic applications in wound healing, muscle recovery, and various inflammatory conditions.

Category

Regene

Sequence

Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln (Ac-LKKTETQ)

Molecular Weight

Approximately 889.01 g/mol

Molecular Formula

C38H68N10O14

Half Life

Approximatley 2 to 3 days

Most Common Uses

TB-500 has gained attention for its potential therapeutic applications, primarily based on preclinical studies and anecdotal reports. Its primary uses center on tissue repair and recovery, particularly in contexts involving injury or inflammation. Athletes and people seeking to enhance healing often explore TB-500 for its ability to promote tissue regeneration. Research in animal models suggests it accelerates the repair of muscles, tendons, and ligaments by stimulating cellular migration and angiogenesis, which supports faster recovery from strains, tears, or overuse injuries.

Additionally, TB-500 is investigated for its potential to improve wound healing, as studies indicate it enhances skin repair by promoting fibroblast activity and collagen deposition. Some reports also highlight its use in reducing inflammation in musculoskeletal conditions, such as tendonitis or joint injuries, where it may alleviate discomfort and support tissue integrity. In veterinary contexts, particularly in equine medicine, TB-500 is explored for similar purposes, aiding recovery from injuries in horses. While these applications show promise in preclinical and anecdotal settings, human clinical trials remain limited, and ongoing research seeks to establish its efficacy and safety for broader therapeutic use.

Mechanism of Action

TB-500 works through several natural processes in the body, based mainly on results from animal studies. It helps repair and rebuild damaged tissues by boosting how cells move and grow, especially cells that build and maintain tissues and blood vessels. This helps the body form new muscle, tendon, and skin structures. TB-500 also supports the growth of new blood vessels by increasing a natural substance that improves blood flow, bringing more oxygen and nutrients to injured areas.

It strengthens the inner structure of cells by improving how certain proteins are built, which helps cells move better and speeds up wound healing and tissue repair. TB-500 also affects inflammation by lowering harmful signals and encouraging healing-friendly ones, creating a more balanced environment for recovery. In joints and muscles, it helps rebuild tissue by supporting collagen growth and organizing the material around cells, making repaired areas stronger.

Some animal research also suggests TB-500 may protect nerves by helping nerve cells survive and lowering stress from harmful molecules after injury. All of these actions together show how TB-500 might help the body heal more quickly in many different types of tissues. While these findings offer useful insight, studies in humans are still limited, and more research is needed to fully understand how TB-500 works and how it could be used as a treatment.

Structure and Pharmacology

TB-500, a synthetic peptide derived from thymosin beta-4, consists of seven amino acids with the sequence Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln (Ac-LKKTETQ). Its molecular formula is C38H68N10O14, and it has a molecular weight of 889.01 g/mol. This water-soluble peptide is designed to mimic a functional segment of thymosin beta-4, a naturally occurring protein involved in tissue repair. The acetylated N-terminus enhances its stability, allowing administration through subcutaneous, intramuscular, or intravenous routes, with potential for oral delivery due to its resistance to gastric degradation. Its compact structure facilitates efficient interaction with cellular components, supporting its therapeutic effects observed in preclinical studies.

Pharmacologically, TB-500 exhibits rapid absorption following administration, with a half-life of less than 2 hours in plasma, as indicated by studies in horses and in vitro human models. Despite its short half-life, its biological effects persist due to its ability to initiate sustained cellular responses. The peptide distributes widely to tissues involved in repair, such as muscles, tendons, and skin, where it interacts with pathways regulating angiogenesis, cellular migration, and inflammation. TB-500 increases a natural substance in the body that helps new blood vessels grow, supports the building of internal cell structures so cells can move and stay strong, and adjusts the body’s response to inflammation to create better conditions for healing. It also boosts the activity of cells that help rebuild tissue and encourages the production of collagen, which helps repair and strengthen damaged areas.

The body likely breaks down TB-500 in the same way it processes other natural proteins, and it is mostly cleared through the kidneys and liver, although the exact breakdown products have not been fully studied. Animal and lab-based research gives us a good idea of how TB-500 works, but studies in humans are still very limited. More research is underway to better understand how it behaves in the body and how it might be used as a treatment.

Dosages

TB-500 dosage information primarily derives from preclinical studies and anecdotal reports, as standardized human dosing protocols remain undefined due to the absence of extensive clinical trials. In animal studies, particularly in horses, doses typically range from 500 mcg per day or 2.5 mg every 3 days, given via intramuscular injection. Regimens vary from single doses to weekly applications over several weeks, depending on the injury treated. Human use, largely based on user experiences, commonly involves subcutaneous or intramuscular injections of 2 to 5 milligrams per dose, administered one to two times per week.

Treatment cycles often span four to eight weeks, followed by maintenance doses or breaks to evaluate outcomes. Due to its stability, oral administration is occasionally explored, though less common, with similar dosing ranges. The lack of regulatory approval and comprehensive human pharmacokinetic data underscores the need for caution, with users tailoring doses based on personal response. Ongoing research aims to establish evidence-based dosing guidelines for therapeutic applications.

Warnings and Cautions

TB-500 does not have approval from authorities for human usage in most countries, and its safety in humans is unknown due to a lack of clinical trials. Long-term effects remain unknown, and repeated or high-dose administration may carry unforeseen risks. Pregnant or breastfeeding women should avoid TB-500, as no data exist on its safety in these groups. Administration via subcutaneous, intramuscular, or intravenous routes requires strict adherence to sterile techniques to prevent infections or complications from improper handling. Some users report mild side effects, such as temporary discomfort at injection sites or mild fatigue, though comprehensive data on adverse reactions are scarce.

Obtaining TB-500 from unregulated sources increases the chance of receiving contaminated or mislabeled products, which could lead to harm. Research in animals suggests potential benefits, but the absence of robust human studies necessitates caution. Ongoing investigations aim to better define TB-500’s safety profile and therapeutic applications.

Research & Clinical Trials

New Directions in Anti-Aging Regenerative Therapies

The study reviewed the role of Thymosin beta-4 (Tβ4) in potentially reversing aging and supporting heart regeneration. Instead of only focusing on damage repair in aging tissues, we might learn from how the body develops during early life, particularly during embryonic stages. They argue that using small molecules involved in early development, such as TB4, could help regenerate organs and repair age-related damage, especially in the heart after injury.

The review highlights how Tβ4, when delivered through the bloodstream, shows promising regenerative effects on heart tissue, improves blood vessel growth, reduces inflammation, and supports tissue survival. Because Tβ4 is small, naturally secreted, and active in various tissues, it may be easier to use therapeutically than larger or more complex treatments like stem cells.

The study also notes that TB-500 has gained interest for its similar regenerative and healing effects. TB-500 has been used in both research and veterinary settings to support tissue repair, reduce inflammation, and improve recovery after injury, making it a practical extension of Tβ4’s therapeutic promise.

Accelerates Wound Healing

Doping Control Analysis

The study found that TB-500 can be clearly detected in horse blood and urine using a sensitive and accurate testing method. Scientists developed a technique called liquid chromatography–mass spectrometry (LC/MS) that can find even tiny amounts of TB-500 and its breakdown products—as low as 0.01 ng/mL in urine and 0.02 ng/mL in plasma. They confirmed this method works by identifying the substance in samples taken from horses that received a single 10 mg dose of TB-500.

This is important not just for scientific reasons, but also because it helps prevent cheating in horse racing. TB-500 is banned in the sport because it may improve performance by helping blood vessels grow, speeding up healing, boosting collagen production, and reducing inflammation. Even though the peptide LKKTETQ naturally exists in the body as part of Thymosin β4, the version used in TB-500 is chemically modified, which makes it more active and easier to spot in tests.

Sourcing

USA

LIMITLESS LIFE NOOTROPICS aka Biotech

Use Discount Code: EP20

SCANTIFIX

Use Discount Code: Exploringpeptides

Canada

BIOSLAB

Use Discount Code: EP10

Europe

DNLABResearch

Use Discount Code: EP15

Australia

LVLUPHEALTH

References

[1] Maar, K., Hetenyi, R., Maar, S., Faskerti, G., Hanna, D., Lippai, B., Takatsy, A., & Bock-Marquette, I. (2021). Utilizing Developmentally Essential Secreted Peptides Such as Thymosin Beta-4 to Remind the Adult Organs of Their Embryonic State-New Directions in Anti-Aging Regenerative Therapies. Cells, 10(6), 1343. https://doi.org/10.3390/cells10061343

[2] Malinda, K. M., Sidhu, G. S., Mani, H., Banaudha, K., Maheshwari, R. K., Goldstein, A. L., & Kleinman, H. K. (1999). Thymosin beta4 accelerates wound healing. The Journal of investigative dermatology, 113(3), 364–368. https://doi.org/10.1046/j.1523-1747.1999.00708.x

[3] Ho, E. N. M., Kwok, W. H., Lau, M. Y., Wong, A. S. Y., Wan, T. S. M., Lam, K. K. H., Schiff, P. J., & Stewart, B. D. (2012). Doping control analysis of TB-500, a synthetic version of an active region of thymosin β4, in equine urine and plasma by liquid chromatography–mass spectrometry. Journal of Chromatography A, 1265, 57-65. https://doi.org/10.1016/j.chroma.2012.09.043

Related articles

SLU-PP-915: Benefits, Research & Comparison with SLU-PP-332

Adalank vs Selank: Differences, Benefits and Effects

Adamax vs Semax: Comparison, Benefits, and Effects

Common Mistakes When Reconstituting Peptides

Peptides Vs Proteins: What’s The Difference?

What Are Peptides and How Do They Work?

CONNECTED / MODULES

Post-session references

Selected from shared article topics. Source links are retained where available.

01

Handling & safety lane

Source-derived education, not individual medical guidance or an instruction to dose.

STORAGE

Debunking Common Misconceptions Around Peptide Storage

We've encountered a few persistent myths surrounding peptide storage, particularly concerning the question does TB-500 need refrigeration and related compounds. Let's clear some of them up: Myth 1: 'It'll be fine at room temperature for a little while.' While lyophilized peptides have some room temperature stability, 'a little while' is subjective and risky. Why gamble with your research? Even brief exposures can initiate degradation that compounds over time. For reconstituted peptides, 'a little while' can mean significant degradation within hours. Myth 2: 'Any freezer will do.' A household freezer, with its frequent temperature swings from opening and often rudimentary temperature control, isn't ideal for long-term peptide storage. A laboratory-grade freezer offering stable -20°C or -80°C is vastly superior. This isn't just a recommendation; it's a best practice for preserving sensitive biologicals. Myth 3: 'Once it's reconstituted, it lasts forever in the fridge.' Nope. While refrigeration significantly extends the life of reconstituted peptides, it doesn't make them immortal. Degradation still occurs, just at a slower rate. Always adhere to recommended shelf-life guidelines for reconstituted solutions, typically a few weeks to a month at most for most peptides, including TB-500 (thymosin Beta-4). These misconceptions can lead to compromised results, and frankly, unnecessary frustration. We're here to help you navigate these challenges with clear, evidence-based advice.
02

Question drills

Open a question for its connected answer.

01What If Different Cell Types Respond Differently to TB-500?+

They do. And that's the point. Fibroblasts, endothelial cells, macrophages, and stem cells all express different levels of actin-binding proteins and respond to TB-500 with tissue-specific effects. Researchers should select cell models that match their target tissue application. Using HUVECs to study angiogenesis is appropriate; using HUVECs to model bone repair is not.

SOURCE / realpeptides.co ↗
02What If I Stop TB-500 After 16 Weeks — Do Results Reverse?+

Partially. Follicles activated by TB-500 will complete their current anagen cycle (2–6 years for scalp hair), but once the peptide clears from circulation, dormant follicles won't receive continued activation signals. New hairs grown during the protocol remain until their natural cycle ends, but density won't continue improving without ongoing dosing. This mirrors minoxidil dynamics: withdrawal doesn't cause immediate shedding, but gradual return to baseline over 6–12 months as newly activated follicles re-enter telogen without further stimulus.

SOURCE / realpeptides.co ↗
03What If I Experience Injection Site Reactions or Systemic Side Effects?+

Stop immediately and consult a physician. While preclinical studies show minimal toxicity, individual responses vary. Reported side effects in anecdotal case reports include injection site erythema (redness), transient headache, and mild fatigue. There are no documented cases of anaphylaxis or severe immune reactions, but the absence of large-scale human trials means rare adverse events might not yet be identified. If symptoms persist beyond 48 hours or worsen, discontinue use.

SOURCE / realpeptides.co ↗
04What If You Need to Combine TB-500 With Other Growth Factors?+

TB-500 synergizes with VEGF, FGF-2, and PDGF through non-overlapping mechanisms. Combination treatment routinely produces additive or super-additive effects. Apply growth factors at standard concentrations (VEGF 20–50 ng/mL, FGF-2 10 ng/mL) and TB-500 at 200 ng/mL simultaneously; the growth factors provide directional cues (chemotaxis) while TB-500 enhances cellular capacity to respond (cytoskeletal readiness). Avoid combining with other actin-binding peptides (phalloidin, cytochalasin analogs) that compete for the same binding sites and create unpredictable cytoskeletal effects.

SOURCE / realpeptides.co ↗
05What If the Peptide Arrives Warm After Shipping?+

Check the supplier's shipping method. Reputable peptide suppliers ship lyophilised peptides with cold packs or dry ice and include a temperature indicator strip inside the package. If the indicator shows temperatures exceeded 25°C for more than 6 hours, contact the supplier immediately and request a replacement. Do not assume the peptide is still viable. TB-500 in lyophilised form tolerates brief ambient temperature exposure (under 4 hours at room temperature), but prolonged heat exposure denatures the tertiary structure irreversibly. The peptide may look identical but be functionally inactive.

SOURCE / realpeptides.co ↗
03

Evidence cooldown

Research context and source excerpts for a slower second read.

RESEARCH

Notable Studies:

Thymosin beta4 enhances repair by organizing connective tissue and preventing the appearance of myofibroblasts The effect of thymosin treatment of venous ulcers A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin beta4 in healthy volunteers

RESEARCH

What Are the Safety and Handling Considerations in Research?

Because there is no clinical safety database for TB-500 in neuroregeneration, “safety” in this domain refers to laboratory handling discipline rather than a human risk profile. Sound practice includes verifying peptide identity and purity by analytical methods before use; documenting reconstitution calculations and lot information; storing lyophilized and reconstituted material under appropriate conditions to preserve stability; and using sterile technique to avoid contamination that could confound biological readouts. Given the fragment-versus-full-length labeling problem, characterization is not optional — it is the difference between studying the molecule you think you are studying and an unknown mixture. All work should conform to the institution’s biosafety and research-ethics requirements, and results should never be extrapolated into human dosing or therapeutic claims. It is also worth stating plainly what the research-only status means for the human-safety unknowns. Because there are no controlled human neuroregeneration trials, there is no systematic characterization of immunogenicity, no dose–toxicity relationship, no data on interactions with concurrent conditions or medications, and no long-term follow-up for outcomes such as unwanted angiogenesis. The pro-angiogenic activity that makes Tβ4 attractive for repair is, in a different context, a theoretical liability — agents that promote new vessel growth warrant scrutiny for effects on any occult neoplastic tissue, a question that simply has not been studied for chronic TB-500 exposure in humans. None of this is a claim that harm has been demonstrated; it is a statement that the safety questions have not been asked and answered in the rigorous way that approval requires. Absence of evidence of harm is not evidence of absence of harm, and that gap is itself a core reason the compound remains confined to research settings.

05

Product & matchup locker

Linked catalog and comparison files.

Continue reading

Related articles